Mandate

Vinge advised LumenRadio AB (publ) in connection with the listing on Nasdaq First North Growth Market

Vinge has advised LumenRadio AB (publ) (“LumenRadio”) in connection with its listing on Nasdaq First North Growth Market. The prospectus was published on 28 November 2022 and the first day of trading occurred on 8 December 2022.

The offering in connection with the listing was conducted at a fixed price of SEK 48 per share, corresponding to a market value for LumenRadio’s shares of approximately SEK 544 million before the offering and approximately SEK 594 million after the completion of the offering.

LumenRadio is a Gothenburg based technology company focusing on developing and selling reliable wireless product-to-product connections for business-critical applications within the Internet of Things (“IoT”). LumenRadio offers scalable solutions that build on proprietary and patented technology for future-proof wireless data transfer on open frequency bands, replacing traditional cables for control and automation. LumenRadio has around 60 employees and is headquartered in Gothenburg, with two small sales offices in Frankfurt and Boston.

Vinge’s team primarily consisted of Magnus Pauli, Edin Agic (Project Manager), Petronella Hallberg, Adrian Filipovic, Amelia Rihs, Hanna Jansson (Capital Markets and Public M&A), Anna Högsten, Victoria Gunnerek (Employment and Sanctions) and Amanda Stoltz (VDR).

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025